After plugging billions into its manufacturing network to meet rampant demand for Mounjaro and Zepbound, Eli Lilly is looking ...

Eli Lilly has asked to join in opposing a lawsuit brought by compounding pharmacies against the U.S. Food and Drug ...

Eli Lilly’s request to intervene in a suit filed by compounding pharmacies against the FDA reflects a belief the outcome ...

The story of Eli Lilly and Novo Nordisk’s GLP-1 dominance is likely to play out again in 2025 as the metabolic medicine ...

Eli Lilly moves to defend FDA's tirzepatide shortage resolution amid criticism over supply issues and compounding pharmacy ...

The weight loss medication tirzepatide (Mounjaro and Zepbound) is no longer in shortage, according to the FDA. Access to ...

Eli Lilly (LLY) is reportedly seeking to oppose a lawsuit filed by compounding pharmacies over the FDA's determination that ...

Tirzepatide is the active ingredient in the FDA-approved versions of the drug, Mounjaro and Zepbound, which are made by the ...

According to leading data and analytics company GlobalData, Eli Lilly’s Zepbound (tirzepatide) is poised to surpass Novo Nordisk’s Wegovy (semaglutide), despite expectations for continued ...

In a win for patients, the judge overseeing Lilly’s International Trade Commission case determined that U.S. Customs ...

Eli Lilly’s weight-loss drug tirzepatide has become the first drug for obstructive sleep apnea, a common but serious sleep ...